electroCore (ECOR) investor relations material

Executive summary

• Net sales for Q2 2026 reached $9.5 million, up 28% year-over-year, driven by VA prescription sales, Quell, and Truvaga growth.

• Net loss improved by 17% to $3.1 million, with adjusted EBITDA loss improving 26% year-over-year.

• Raised 2026 revenue guidance to over 30% growth, citing accelerating momentum and operational improvements.

• Significant sales force transformation included doubling sales regions and onboarding 17 new representatives to expand VA coverage and drive diversified account growth.

• The company faces substantial doubt about its ability to continue as a going concern due to ongoing losses and cash burn.

Financial highlights

• Q2 2026 net sales: $9.5 million (up from $7.4 million in Q2 2025); gross profit: $8.2 million; gross margin: 86.5%.

• Research and development expense rose to $800,000, reflecting increased studies and app development.

• Selling, general, and administrative expense was $10.1 million, mainly due to higher sales and marketing costs.

• Net loss per share improved to $0.33 from $0.44 in Q2 2025.

• Cash, equivalents, and marketable securities totaled $10 million at quarter-end.

Outlook and guidance

• Full-year 2026 revenue growth now expected to exceed 30% over 2025.

• Targeting positive adjusted EBITDA by Q3 2027.

• Operating leverage expected to improve as expanded sales infrastructure matures.

• Forecasted cash is insufficient to fund planned operations for the next 12 months, raising substantial doubt about going concern.